key: cord-0885344-d1q1n5m8
authors: Açar, Burak
title: Letter: Multiple Factors Could Affect Blood Pressure in Patients With COVID-19
date: 2022-03-03
journal: Angiology
DOI: 10.1177/00033197221082335
sha: 71ca56a19e05368d12335154ff784397bb4b6323
doc_id: 885344
cord_uid: d1q1n5m8

nan

Dear Editor, I have some comments regarding the interesting article entitled "Does COVID-19 Cause Hypertension?". 1 So far, there is not much evidence as to whether COVID-19 can cause high blood pressure (BP) in previously normotensive patients. Li et al 2 reported that the prevalence of hypertension in patients with COVID-19 was 17.1%.

It would be of interest to consider some points regarding this study. 1 Firstly, BP measurements were carried out in a hospital setting using a sphygmomanometer. Despite precautions for obtaining valid measurements, this can cause white coat hypertension. Recent guidelines suggest that BP should initially be measured in both arms, using an appropriate cuff size. 3 The author only used the right arm and a sphygmomanometer was used; semiautomatic or automatic sphygmomanometers could have been a better option in these patients.

The author excluded patients on steroid therapy before the start of the study. Most patients in this study 1 received chloroquine/hydroxychloroquine and favipiravir treatment. Although there is not much evidence whether these drugs alter the BP, studies which were mostly conducted on the animals showed that chloroquine might lower BP. [4] [5] [6] Furthermore, a study 7 showed that a single high dose of chloroquine could reduce BP in young adults. 7 The authors suggested that the hypotensive effect could at least in part be attributed to the vasodilatory effect of chloroquine. 7 Analysis involving confounding factors could be more suitable to define the predictive value of COVID-19 regarding the development of hypertension.

Burak Açar, MD  https://orcid.org/0000-0003-3217-5000

Does COVID-19 cause hypertension? Angiology

Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China

ESC/ESH Guidelines for the management of arterial hypertension

Autoimmune therapeutic chloroquine lowers blood pressure and improves endothelial function in spontaneously hypertensive rats

Chloroquine suppresses the development of hypertension in spontaneously hypertensive rats

Pharmacological and cardiovascular perspectives on the treatment of COVID-19 with chloroquine derivatives

Chloroquine reduces blood pressure and forearm vascular resistance and increases forearm blood flow in healthy young adults